Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

Exclusion Criteria

• •Clinically significant medical conditions including active or uncontrolled infections, new or recurrent malignancy, serious cardiac, pulmonary, or renal disease, and uncontrolled diabetes.
• •Karnofsky Performance Score \< 60.
• •Immunosuppressant therapies other than allowed background therapy
• •Anti-arrhythmic and heart rate lowering drugs.
• •Any other circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol